The EIF1B Knockout Raji Polyclonal Cells product comprises a heterogeneous population of Raji B lymphocytes with CRISPR/Cas9-mediated disruption of the EIF1B gene. This pooled format provides a robust loss-of-function model for studying the role of the translation initiation factor EIF1B in a B-cell context, avoiding clonal selection artifacts.
Raji is a well-characterized EBV-immortalized B lymphoblastoid cell line derived from a patient with Burkitt lymphoma. These cells lack surface immunoglobulin but express key B-cell markers such as CD21 (complement receptor 2), making them a valuable model for B-cell biology, EBV-driven lymphomagenesis, and humoral immunity studies.
EIF1B functions as a fidelity factor in translation initiation, cooperating with eIF1 and eIF1A to ensure accurate start codon recognition by the 43S preinitiation complex. It interacts with eIF2-GTP-Met-tRNAi ternary complex, eIF3, eIF5, and the 40S ribosomal subunit to prevent premature AUG recognition and maintain scanning processivity. EIF1B activity is modulated by upstream regulators such as mTORC1 signaling, MYC transcription factor activity, and nutrient availability, linking translation control to cellular growth and stress pathways. Downstream, it influences translation initiation of uORF-containing mRNAs and global translation fidelity, thereby affecting the expression of oncogenes like MYC and CCND1. In the integrated stress response and ribosome-associated quality control pathways, EIF1B contributes to translational reprogramming under stress.
In Raji cells, which represent a model of EBV-associated B-cell lymphoma, disruption of EIF1B is particularly relevant given the dependence of these tumor cells on dysregulated translation for proliferation and survival. The MYC oncogene, a central driver in Burkitt lymphoma, is among the downstream targets affected by altered translational fidelity. Additionally, the EBV status and B-lymphocyte identity of Raji cells enable investigation of how EIF1B loss impacts viral and host mRNA translation, stress granule dynamics, and immune recognition pathways. This polyclonal knockout population captures diverse editing outcomes, allowing assessment of dose-dependent or heterogeneous phenotypes within a pool.
Researchers can employ the EIF1B Knockout Raji Polyclonal Cells in varied experimental paradigms, including ribosome profiling to map start site selection shifts, dual-luciferase reporter assays to quantify uORF-mediated regulation, and polysome profiling to evaluate global translation changes. Additional functional readouts include puromycin incorporation assays for translation rates, Western blotting for target protein levels, and flow cytometry for cell cycle and apoptosis analysis. The model also supports chemosensitivity screens to identify translation-dependent vulnerabilities and investigations into EBV-host interactions. For further details on product specifications and technical support, please contact Ascent Research.
